Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.
Augustin M, Gottlieb AB, Lebwohl M, Pinter A, Warren RB, Puig L, Warham R, Lambert J, Wiegratz S, Szilagyi B, Blauvelt A. Augustin M, et al. Among authors: warren rb. Dermatol Ther (Heidelb). 2024 Oct;14(10):2841-2857. doi: 10.1007/s13555-024-01261-6. Epub 2024 Sep 17. Dermatol Ther (Heidelb). 2024. PMID: 39285121 Free PMC article.
Psoriasis: is the impairment to a patient's life cumulative?
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Kimball AB, et al. Among authors: warren rb. J Eur Acad Dermatol Venereol. 2010 Sep;24(9):989-1004. doi: 10.1111/j.1468-3083.2010.03705.x. Epub 2010 May 7. J Eur Acad Dermatol Venereol. 2010. PMID: 20477920
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.
Reich K, Zschocke I, Bachelez H, de Jong EM, Gisondi P, Puig L, Warren RB, Mrowietz U; TTOP study group. Reich K, et al. Among authors: warren rb. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1156-63. doi: 10.1111/jdv.12774. Epub 2014 Oct 26. J Eur Acad Dermatol Venereol. 2015. PMID: 25346093 Free article. Clinical Trial.
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).
Reich K, Zschocke I, Bachelez H, de Jong EMGJ, Gisondi P, Puig L, Warren RB, Ortland C, Mrowietz U; PSO-TOP study group. Reich K, et al. Among authors: warren rb. Br J Dermatol. 2017 Jul;177(1):197-205. doi: 10.1111/bjd.15466. Epub 2017 Jun 6. Br J Dermatol. 2017. PMID: 28301043 Clinical Trial.
Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB. Blauvelt A, et al. Among authors: warren rb. Br J Dermatol. 2017 Sep;177(3):879-881. doi: 10.1111/bjd.15656. Epub 2017 Aug 9. Br J Dermatol. 2017. PMID: 28498514 Clinical Trial. No abstract available.
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
Guenther L, Warren RB, Cather JC, Sofen H, Poulin Y, Lebwohl M, Terui T, Potts Bleakman A, Zhu B, Burge R, Reich K, van de Kerkhof P. Guenther L, et al. Among authors: warren rb. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4. J Eur Acad Dermatol Venereol. 2017. PMID: 28573743 Clinical Trial.
European consensus statement on phenotypes of pustular psoriasis.
Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, Kingo K, Smith C, Barker JN; ERASPEN Network. Navarini AA, et al. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1792-1799. doi: 10.1111/jdv.14386. Epub 2017 Aug 29. J Eur Acad Dermatol Venereol. 2017. PMID: 28585342 Free article. Review.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D. Reich K, et al. Among authors: warren rb. Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18. Br J Dermatol. 2020. PMID: 31218661 Free PMC article.
330 results